本报讯(记者陈潇)近日，半岛大超炮、半岛逆时针这两款刚斩获NMPAⅢ类医疗器械注册证的重磅产品 同台亮相头部能量源医美器械企业深圳半岛医疗集团股份有限公司(以下简称"半岛医疗")2026新品发布 会北京站。 据悉，半岛大超炮与半岛逆时针，分别锁定深层支撑与浅层修护，通过医工结合的高精尖技术，实现了 从筋膜层到表皮层的全方位贯通。据悉，半岛医疗旗下产品如今远销全球70多个国家和地区、覆盖国内 外上万家医院与医美机构。 半岛医疗创始人、董事长雷晓兵表示："我们的初心朴素而坚定，就是让中国上千家医院，都能买得 起、用得起曾被国际巨头垄断的尖端医疗设备。" 这份坚守的核心，源于半岛独有的"医工结合"模式。近400人的研发团队，构建起一座连接一线临床需 求与工程技术的"桥梁"——既能精准捕捉到临床一线医生和患者的痛点诉求，又能快速将需求转化为可 落地的技术方案。 中国整形美容协会会长张斌在致辞中表示："一个行业，如果不去抓创新、搞科研，是没有希望的。半 岛在超声、激光、微针领域花大量时间持续搞创新，走科研创新这条路，走对了。尽管可能很困难，但 这条路终是宽广的。" 据悉，半岛医疗在2018年调整了研发方向：必须攻克"疗 ...

中国经济网北京1月8日讯（记者 李方） 1月7日，半岛大超炮、半岛逆时针这两款刚获得NMPA III类医 疗器械注册证的产品亮相半岛医疗2026新品发布会北京站。与此同时，半岛产品已获得美国FDA、欧盟 CE等多项认证，跻身全球主流医美市场。源自中国临床医生的实战洞察、凝聚中国工程师智慧的技术 方案，正从"跟跑"转向"并跑"，开始参与塑造全球医美器械的竞争格局。 北京医院整形外科主任、教授赵红艺指出，作为风险管理等级最高的"三类有源医疗器械"，半岛逆时针 射频皮肤治疗仪获取械三认证，是其安全性与有效性的最高标准确认。其针对面部萎缩性痤疮瘢痕的多 中心临床研究数据显示，术后三个月瘢痕改善有效率达96%，受试者满意度高达97.5%。 第三方市场研究机构沙利文的数据显示，中国已成为全球增长最快的光电抗衰市场，其中超声与射频微 针两大赛道合计占比超60%，成为行业核心增长引擎。 "相信未来，中国的医美器械企业与服务机构必将走向世界，成为全球级的品牌。我们坚定看好中国医 美行业，期待中国品牌，世界共享。"雷晓兵说。 据介绍，半岛大超炮将高分辨率智能超声影像系统与治疗流程深度融合，推出SOP 3.0精准治疗体系， 构建起 ...

Core Insights - Peninsula Medical is experiencing rapid growth in user trust, with over 1 user receiving anti-aging or skin rejuvenation treatments every minute, and its core products have treated over 4 million users [1] - The company launched two new products, "Peninsula Big Ultrasound" and "Peninsula Counterclockwise," both of which received the highest medical device certification in China [1] - The market for anti-aging treatments in China is rapidly expanding, with 99.7% of consumers considering anti-aging important, creating significant demand for Peninsula's new products [2] Product Performance - The "Peninsula Big Ultrasound" has gained significant market attention since its NMPA III class certification, quickly becoming a trending product on social media [2] - The product's strong market performance is evidenced by high user satisfaction and repeat purchase rates, indicating its potential as a market leader [2][3] - Clinical trials for the "Peninsula Counterclockwise" show over 96% effectiveness in scar improvement and high user satisfaction rates [5][6] Technological Advancements - The "Peninsula Counterclockwise" is the first domestic product to receive both NMPA and FDA certifications, addressing key industry challenges by balancing effectiveness and comfort [4] - The "Peninsula Big Ultrasound" features advanced technology that improves energy efficiency by over 50% compared to previous models, enhancing treatment comfort and precision [5] Industry Impact - Peninsula Medical's commitment to social responsibility is highlighted by its participation in charity auctions, setting a new record in the beauty industry [3] - The company has established a strong research and development foundation, with over 1,000 patent applications and a dedicated team of nearly 400 researchers [7] - Through training programs, Peninsula Medical has certified over 12,000 professional physicians, contributing to the overall improvement of industry standards [8] Strategic Vision - Peninsula Medical aims to lead the high-end medical aesthetics market in China and globally, focusing on long-term growth and innovation [9] - The company emphasizes the integration of scientific research and clinical practice to enhance user experience and product effectiveness [9]

近日，在半岛医疗 2026 年新品发布会上，公司两款重磅产品 —— 半岛大超炮、半岛逆时针一一亮 相。 其中，半岛大超炮是首个拿到了 国家药监局 三类医疗器械注册证的聚焦超声皮肤治疗仪，而半岛逆 时针则是首个拥有 国家药监局 NMPA 与美国 FDA 双认证的国产三类射频皮肤治疗仪。 这两款产品均凝结了公司多年的技术攻坚与研发创新成果。在业内看来，这两款产品的出现，正在引 领 医 美医疗设备行业进一步走向规范，同时也代表着国产 医美设备 技术正在逆袭，迈入全球市场 竞争。 在 颜值经济 浪潮席卷下，伴随着光电技术等发展，轻医美正在重塑 医 美市场格局。光电 医 美也因 创伤小、恢复快、适合皮肤日常管理，深受消费者追捧。 引领行业走向规范 早在 2012 年，半岛医疗便前瞻性将聚焦超声、射频技术作为未来十年的主攻技术方向 。 此次半岛医疗推出的半岛大超炮、半岛逆时针，是产品技术多次迭代后的成果，并且经过了严谨的临 床试验验证。 2021 年，半岛医疗便前瞻性启动三类临床与注册申请，系统开展临床试验，成为当时国内极少数探 索三类注册证的 医 美器械企业。 医疗器械的注册认证，三类认证与心脏起搏器、人工关节等植入式 ...

Core Insights - Peninsula Medical has launched two significant products, the Peninsula Super Cannon and the Peninsula Counterclockwise, which are set to lead the medical aesthetics equipment industry towards standardization and represent a breakthrough for domestic technology in the global market [1][4][27]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration from the Chinese National Medical Products Administration (NMPA) [1][27]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to achieve dual certification from both the NMPA and the U.S. FDA [1][27]. Industry Impact - The introduction of these products is seen as a move towards standardization in the medical aesthetics industry, which is increasingly influenced by the "beauty economy" and advancements in photonic technology [5][12]. - The medical aesthetics equipment market in China has significant growth potential, with the penetration of photonic medical aesthetics technology driving the development of downstream services [16][30]. Research and Development - Peninsula Medical has invested heavily in R&D, allocating over 25% of its revenue annually, and has a dedicated R&D team of nearly 400 people, constituting 30% of its total workforce [21][27]. - The company has filed over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [21]. Clinical Validation - The clinical trials for the Peninsula Super Cannon involved 204 subjects, showing an efficacy rate of over 82% in improving skin laxity, with a satisfaction rate exceeding 88% three months post-treatment [7][9]. - The clinical data for the Peninsula Counterclockwise indicated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after the procedure [9]. Market Position - Peninsula Medical has positioned itself among the top six global energy source medical aesthetics equipment companies, with its products sold in over 70 countries and regions, serving more than 10,000 well-known hospitals [27]. - The launch of these products marks a shift in the domestic medical aesthetics equipment landscape, moving from low-end market competition to achieving international certifications and recognition [27][30].

Core Viewpoint - The article highlights the rapid growth of China's medical aesthetics equipment industry, showcasing the emergence of domestic brands like Peninsula Medical, which are gaining market share and technological advancements in the field [3][19]. Industry Growth - The domestic medical aesthetics equipment market is projected to exceed 32 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13%-15% [3]. - The market share of domestic equipment has increased from 38% in 2020 to 42% in 2024, with energy source segments like radiofrequency and intense pulsed light reaching a 46% share [3]. Product Innovation - Peninsula Medical's two core products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, represent significant advancements in energy source medical aesthetics devices, with a focus on clinical needs and technological innovation [3][5]. - The Peninsula Ultra Cannon is the first and only ultrasound medical aesthetics device to receive NMPA Class III certification, achieving precise anti-aging treatment from the epidermis to the SMAS layer [3][5]. - The Peninsula Counterclockwise is the first domestic radiofrequency medical aesthetics device to obtain NMPA Class III certification, featuring innovative technologies for effective treatment [5][7]. Clinical Research and Efficacy - Clinical studies led by top hospitals show that the Peninsula Ultra Cannon has an effectiveness rate of over 89% in improving skin laxity, with a satisfaction rate exceeding 90% among participants [5]. - Since its launch in 2021, the Peninsula Ultra Cannon has been used in over 4 million treatments, averaging more than 3,000 treatments per day [5]. R&D and Patents - Peninsula Medical has a strong focus on R&D, with nearly 400 staff dedicated to research, accounting for 30% of total employees, and R&D investment representing 25%-27% of sales revenue [9]. - The company has filed over 1,000 domestic and international patents, with more than 70 global certifications, and has played a role in drafting industry standards [9][19]. International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of China's medical aesthetics professionals [11]. - Peninsula Medical's collaboration with Boston Aesthetics aims to bridge the gap between Chinese R&D and U.S. clinical needs, facilitating the entry of Chinese products into the global market [12][18]. Market Trends - The export value of domestic medical aesthetics equipment is expected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [19]. - The industry is transitioning from a focus on cost-effectiveness to differentiation, with domestic companies targeting specific needs of Asian skin types [14][19]. Future Outlook - The integration of artificial intelligence with medical aesthetics devices is emerging as a new trend, enabling personalized treatment parameters [19]. - The industry is poised for a comprehensive upgrade from "Made in China" to "Intelligent Manufacturing in China," driven by companies focused on R&D and clinical needs [19].

Core Insights - Peninsula Medical showcased its brand on the Nasdaq screen, highlighting its rapid growth in the Chinese medical aesthetics industry, with the domestic medical aesthetic equipment market projected to exceed 32 billion yuan by 2024, maintaining a compound annual growth rate of 13%-15% [1][11] - The company presented two NMPA Class III certified products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, in collaboration with Boston Aesthetics and numerous Chinese dermatologists and plastic surgeons [1][2] Industry Growth - The domestic medical aesthetic equipment market is expected to grow significantly, with the share of domestic equipment increasing from 38% in 2020 to 42% in 2024, particularly in energy source segments like RF and IPL, where domestic brands now hold a 46% market share [1][11] - The clinical demand drives technological innovation, with Peninsula Medical focusing on addressing industry pain points through medical-engineering collaboration [2][3] Product Innovation - The Peninsula Ultra Cannon is the first globally to receive NMPA Class III certification for ultrasound medical aesthetics, achieving over 89% effectiveness in improving skin laxity in clinical studies [2][3] - The Peninsula Counterclockwise is the first domestic RF medical aesthetic device to receive NMPA Class III certification, featuring innovative technologies for precise depth control in clinical applications [3][4] Research and Development - Peninsula Medical has a robust R&D team of nearly 400, accounting for 30% of its workforce, with R&D investment constituting 25%-27% of sales revenue, which is high for the industry [4][5] - The company has filed over 1,000 domestic and international patents and has received more than 70 global certifications, contributing to the industry's shift from imitation to independent innovation [5][11] International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of Chinese medical aesthetics professionals [6][11] - Peninsula Medical's Boston Aesthetics team is pivotal in bridging Chinese R&D with U.S. clinical needs, having successfully registered the Peninsula Counterclockwise in the U.S. [7][10] Market Trends - The international competitiveness of domestic devices is shifting from cost-effectiveness to differentiated advantages, focusing on the unique characteristics of Asian skin [8][9] - The export value of domestic medical aesthetic devices is projected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [11]

Core Insights - The first domestic radiofrequency microneedle device, known as "Haidao Reverse Time," has received the Class III medical device registration certificate in China, marking a significant regulatory milestone for the company [1][2] - This device is the first in China to obtain both NMPA and FDA certifications, aligning with regulatory trends for radiofrequency products [2] - The approval of "Haidao Reverse Time" is expected to accelerate the expansion of domestic radiofrequency products, as companies aim to meet the upgraded regulatory standards [3] Regulatory Developments - The approval of the Class III medical device certificate aligns with the regulatory direction for radiofrequency products, as outlined in the announcement by the drug administration in July 2024 [2] - Starting from April 1, 2026, radiofrequency treatment devices will need to upgrade from Class II to Class III medical device registration, prompting companies to adapt quickly [2][3] Product Features and Market Impact - "Haidao Reverse Time" integrates monopolar, bipolar, and combined modes of radiofrequency microneedling, enhancing treatment efficiency and patient comfort [2] - The device is primarily used for treating acne and offers significant time savings and reduced discomfort compared to traditional methods [2] - The regulatory upgrade is expected to filter out less capable companies, fostering a shift from quantity expansion to quality competition in the domestic radiofrequency product market [3]

Core Insights - Peninsula Medical's product ZenTite has been installed at the Wellman Center for Photomedicine in Boston, marking a significant step in the company's global strategy and showcasing the international presence of Chinese medical aesthetic brands [1][2] - The Wellman Center, affiliated with Harvard Medical School, is a leading institution in photomedicine research and clinical applications, enhancing the credibility of the installation [1] - Dr. R. Rox Anderson, a prominent figure in laser science and medicine, led the installation, highlighting the product's acceptance by influential experts in the field [1][3] Company Developments - Since obtaining FDA 510(k) registration for its Golden Microneedle in early 2023, Peninsula Medical has accelerated the deployment of its major equipment in six renowned hospitals in the U.S., including five installations of ZenTite [2] - The company has also successfully installed its ultrasound device at the Beckman Laser Institute & Medical Clinic, marking its first entry into the U.S. market with this product [2][3] Industry Position - Peninsula Medical is recognized as a leading brand in the global photomedicine and aesthetic device market, with a strong emphasis on collaboration with clinical experts to drive product development [3][4] - The company has a significant R&D workforce, with nearly 400 researchers, representing 30% of its total employees, and holds an 80% market share in the domestic ultrasound aesthetic sector [4]